Cancer Advances Announces Strategic Addition to Clinical Team with Appointment of Jill P. Smith M.D., as Director of Clinical Oncology and Gastroenterology

Durham, NC, October 15, 2014 — Cancer Advances, Inc., a biotechnology portfolio company of Cato BioVentures, announces the addition of Dr. Jill P. Smith, M.D. to the Cancer Advances Team. Dr. Smith is an expert in the field of gastrointestinal cancers, with unparalleled expertise in gastrin mediated pathogenesis. She is currently Professor of Medicine at Georgetown University. Prior to her most recent appointment at Georgetown, she served as the Director of Clinical and Translational Research at the National Institutes of Health (NIDDK).

As a clinician scientist and board certified gastroenterologist, Dr. Smith has been involved in bench to bedside translational research for over 25 years. The main body of her extensive publication record has focused on cancer biology & immunology with a spotlight on gastrointestinal malignancies. The Smith Lab pioneered the work characterizing the interactions of gastrin with the Cholecystokinin receptor in GI cancer. In addition, she was received the European Basic Science award for the discovery of a splice variant of the CCK receptor in pancreatic cancer. Evidence of her national recognition rests in that her colleagues elected her as the first female President of the American Pancreas Association. She is a co-inventor of 8 issued patents and has designed and conducted multiple clinical trials.

Lynda Sutton, President of Cancer Advances commented, “Dr. Smith will play a critical role for Cancer Advances as we enter the home stretch in pursuit of Marketing Approval. Not only is she a bona fide visionary and thought leader in the development of therapeutics for gastrointestinal tumors, but with Jill’s background in all gastrin mediated diseases, she serves as the perfect resource to help us reach the finish line in our initial indication, and to accelerate the development of our technology for additional target populations.”
About Polyclonal Antibody Stimulator (PAS)

PAS, also referred to as G17DT, is a cancer immunotherapeutic agent that induces antibodies against the hormone, gastrin 17(G17), and its precursor, (gly)G17. In animal models and in human subjects, antibodies elicited by PAS inhibit the growth of human gastric, pancreatic, and colorectal cancer. PAS has been tested in multiple clinical trials and cleared for development in 17 North American and European countries. Twenty clinical studies of PAS for the treatment various GI tumors have been conducted to date in over 1500 patients. The safety profile, as assessed by adverse events (AEs) and laboratory parameters, is favorable with no indication of any significant safety concerns, in contrast to the toxicity profile of cytotoxic anticancer agents.

About Cancer Advances

Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal and other cancers by enhancing a patient’s adaptive immune system. The company is supported by the breadth and depth of expertise at CATO Research Ltd. and CATO BioVentures. Senior Management at Cancer Advances combines decades of experience in oncology and biological drug development. Cancer Advances has developed an intellectual property strategy that currently holds over 100 U.S. and worldwide patents and patent applications related to PAS. This broad intellectual property portfolio includes composition and use-protection for PAS.

About CATO Research

Founded in 1988 by Lynda Sutton and Dr. Allen Cato and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service global contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, India, and South Africa, Cato Research consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their sponsors’ products to market with speed and cost-effectiveness. For more information about Cato Research, visit www.Cato.com.
About CATO BioVentures

Cato BioVentures is the venture capital affiliate of Cato Holdings. For over 5 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital® in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry’s research and development productivity. When strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in the company’s overall success. For more information about Cato BioVentures, call 919-361-2286 or visit www.CatoBioVentures.com.

Forward Looking Statements

This release contains certain forward-looking information based upon Cancer Advances’ current plans, beliefs, expectations and projections. Cancer Advances is a privately-held company; any investment decision regarding Cancer Advances should rely only on the investor’s own investigation into Cancer Advances, subject to the terms of the documents governing that investment. In particular, no future results of any clinical trials or regulatory approval are guaranteed.

Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html

Contact: Lynda Sutton
President Cancer Advances, Inc.
Phone: 919-361-2162
Email: info@canceradvancesinc.com
www.canceradvancesinc.com